Insight Molecular Diagnostics (iMDx) announced a favorable Medicare policy expanding reimbursement for donor-derived cell-free DNA (dd-cfDNA) testing, supporting its GraftAssure transplant monitoring assays. The updated policy increases allowable testing frequency for kidney and heart transplant patients, enhancing patient access and encouraging in-house testing at transplant centers. This aligns with iMDx's strategy to commercialize faster, local testing kits pending FDA approval. The policy also cites iMDx research, reinforcing its leadership in transplant diagnostics.
In Q2 filings, major hedge funds like David Tepper's Appaloosa, Dan Loeb's Third Point, and Stanley Druckenmiller's Duquesne Family Office significantly increased holdings in Taiwan Semiconductor Manufacturing (TSMC) while reducing or exiting positio...
This week, the crypto market turned risk-off with Bitcoin dropping below $63,000 amid regulatory concerns and market volatility. Bitway led gains with a 43% rally, supported by strong momentum despite overbought signals. Worldcoin posted an 11% rise,...
Strategy CEO Phong Le identified seven potential catalysts that could energize bitcoin markets this fall, including regulatory exemptions, progress on the CLARITY Act, broader banking adoption, growth in digital credit and money, macroeconomic stabil...
This week is crucial for Bitcoin and XRP as four major events could influence their prices. President Trump will meet crypto leaders and US regulators, including SEC and CFTC heads, to discuss crypto regulation, particularly the stalled Digital Asset...
Tokenized U.S. Treasury bills are expanding across multiple blockchain platforms, with Solana adding $378.2 million in new issuance over 30 days, outpacing Ethereum's $272.2 million. Other blockchains like BNB Chain and zkSync Era also saw growth, wh...
